Speed of remission in elderly patients with depression: electroconvulsive therapy v. medication

Harm-Pieter Spaans, Pascal Sienaert, Filip Bouckaert, Julia F. van den Berg, Esmée Verwijk, King H. Kho, Max L. Stek and Rob M. Kok

Background
Severe depression can be a life-threatening disorder, especially in elderly patients. A fast-acting treatment is crucial for this group. Electroconvulsive therapy (ECT) may work faster than medication.

Aims
To compare the speed of remission using ECT v. medication in elderly in-patients.

Method
The speed of remission in in-patients with a DSM-IV diagnosis of major depression (baseline MADRS score ≥20) was compared between 47 participants (mean age 74.0 years, s.d. = 7.4) from an ECT randomised controlled trial (RCT) and 81 participants (mean age 72.2 years, s.d. = 7.6) from a medication RCT (nortriptyline v. venlafaxine).

Results
Mean time to remission was 3.1 weeks (s.d. = 1.1) for the ECT group and 4.0 weeks (s.d. = 1.0) for the medication group; the adjusted hazard ratio for remission within 5 weeks (ECT v. medication) was 3.4 (95% CI 1.9 – 6.2).

Conclusions
Considering the substantially higher speed of remission, ECT deserves a more prominent position in the treatment of elderly patients with severe depression.

Declaration of interest
None.

Setting and participants
In-patients participating in an RCT comparing ECT techniques were compared with in-patients participating in a medication RCT. The ECT trial studied the efficacy and cognitive side-effects of brief pulse v. ultrabrief pulse unilateral stimuli over a period of 6 weeks in a group of 116 participants (≥18 years). The medication trial studied the efficacy and side-effects of nortriptyline v. venlafaxine over 12 weeks in a group of 81 participants (≥60 years). Both trials included in-patients fulfilling DSM-IV criteria for major depression. The severity of depression was assessed weekly in the ECT trial and in weeks 1, 3, 5, 7, 9 and 12 in the medication trial using the Montgomery–Åsberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HRSD, 17-item version). The diagnosis of major depression was confirmed using the Mini-International Neuropsychiatric Interview in the ECT trial and the International Diagnostic Check List in the medication trial.

Procedure
From the ECT trial, participants aged 60 or over with unipolar depression and with a baseline MADRS score of at least 20 (n = 47) were selected for this study (ECT group). Exclusion criteria were age < 60, MADRS score < 20 or bipolar depression (Fig. 1). Of the included patients 44.7% (n = 21) received brief pulse ECT and 55.3% (n = 26) ultrabrief pulse ECT. From the medication trial, all participants (n = 81) were included (medication group). Of these patients 49.4% (n = 40) were treated with venlafaxine and 50.6% (n = 41) with nortriptyline. For both the ECT and the medication groups assessments were available at baseline and at weeks 1, 3 and 5.
Outcome

The difference between the two groups in the time to achieve remission, defined as a MADRS score <10 within 5 weeks, was the primary outcome measure in this study. The differences in the time to achieve remission based on an HRSD remission score ≤7 and the hazard ratios (HRs) of achieving remission within 5 weeks were defined as secondary outcome measures.

Statistical analysis

We analysed possible differences in baseline variables between the ECT group and the medication group with chi-squared tests for categorical variables and two-sided Student’s t-tests for continuous variables, if normally distributed, or Mann–Whitney U-tests if not. Statistical significance was defined as P<0.05. Differences in mean time in which remission occurred between the ECT group and the medication group were analysed with two-sided Student’s t-test. For a comparison between the trajectories of the ECT and medication groups we performed a Cox proportional hazards model analysis with time to remission as the outcome measure. In the first step we adjusted for age, gender, psychotic depression, severity of depression episode and late onset of first episode (≥55 years) as covariates. Next, we additionally adjusted for duration of the current depressive episode and the number of different antidepressants used to treat the current depressive episode, which could both be considered as a proxy for treatment resistance. In addition we calculated hazard ratios with 95% confidence intervals (CIs) of achieving remission with ECT compared with medication.

As we wished to compare the brief pulse and the ultrabrief pulse subgroups as a whole in the ECT group with the venlafaxine and nortriptyline subgroups taken together in the medication group, we analysed all ECT sample/medication sample comparisons with Cox’s regression models to confirm whether grouping was justified. We used IBM SPSS Statistics for Windows, version 20 for all statistical analyses.

Results

The flow chart of patients is presented in Fig. 1. There were no statistical differences at baseline between the ECT and the medication group in age, gender, proportion of patients with psychotic depression, severity of depression, duration of the current depressive episode and proportion of patients with a late onset of first depression. However, the ECT group had used a greater number of different antidepressants during the current depressive episode compared with the medication group (Table 1).

The mean time to remission based on the MADRS scores was 3.07 weeks (s.d. = 1.11) for the ECT group and 3.95 weeks (s.d. = 1.03; t(47) = −2.781, P = 0.008) for the medication group. The mean time to remission according to the HRSD was 3.07 weeks (s.d. = 1.04) for ECT and 3.50 weeks (s.d. = 1.28; t(35.8) = −1.223, P = 0.229) for the medication group. The hazard ratio for achieving remission within 5 weeks of treatment based on the MADRS for ECT compared with medication adjusted for age, gender, percentage of psychotic depression, severity of depression and percentage late onset of first depression was 3.4 (95% CI 1.9–6.2, P<0.001) (Fig. 2). The hazard ratio after additional adjustment for the duration of the current depressive episode and the number of antidepressants to treat the current episode was 8.2 (95% CI 3.6–19.0, P<0.001). The results for remission defined as a score of ≤7 on the HRSD as secondary outcome were a hazard ratio of 2.7 (95% CI 1.5–4.9, P = 0.001) and 4.5 (95% CI 2.0–10.2, P<0.001) respectively.
Using additional Cox’s regression analysis, both brief pulse and ultrabrief pulse subgroups were compared with both the venlafaxine and the nortriptyline subgroups. The hazard ratio for achieving remission within 5 weeks using the MADRS were, respectively, 3.9 (95% CI 1.7–8.7, P = 0.001) for brief pulse ECT v. nortriptyline; 5.9 (95% CI 2.1–16.6, P = 0.001) for brief pulse ECT v. venlafaxine; 2.3 (95% CI 1.1–5.2, P = 0.036) for ultrabrief pulse ECT v. nortriptyline; and 3.6 (95% CI 1.4–9.2, P = 0.007) for ultrabrief pulse v. venlafaxine.

**Discussion**

**Main findings**

In this study, we have shown that elderly in-patients with severe depression achieved remission, as defined using the MADRS score, significantly faster if treated with ECT in comparison with antidepressants. Using the HRSD we could not confirm this finding, probably because of three missing HRSD assessments in many countries, where ECT will be suggested if a patient has failed at least one or two medication trials. Within 5 weeks 63.8% (30/47) of the patients treated with ECT remitted according to the MADRS scores, compared with only 23.5% (19/81) of the patients treated with medication. The ECT study lasted 6 weeks and no additional patients remitted between week 5 and week 6. In the medication study, however, eight patients achieved remission between week 5 and week 12. The final remission rates of 63.8% (30/47) after 6 weeks in the ECT group and 33.3% (27/81) after 12 weeks in the medication group underlines the superiority of ECT even more (Fig. 1).

Although late-onset depression as well as a psychotic depression have been related to outcome, neither was significantly associated with remission in our study. The proportion with psychotic depression was substantial in both groups. Because ECT is regarded as a preferential treatment for psychotic depression, this could have introduced a bias against antidepressant monotherapy in the comparison. However, a subgroup analysis of the patients with non-psychotic depression rendered a comparable result: the hazard ratio of achieving remission within 5 weeks with ECT (n = 21) v. medication (n = 40) was 3.3 (95% CI 1.3–8.5, P = 0.012) in patients with non-psychotic depression. To compensate for the reduced sample size only baseline MADRS score and duration of the current episode were included as covariates in the analysis.

**Findings from other studies**

We are not aware of any other study using speed of remission as an outcome criterion in elderly patients with depression. In adults only one previous RCT, that included drug naive out-patients with a male preponderance, comparing bilateral ECT (mean age 37.5 years, s.d. = 9.4) v. imipramine (mean age 42.4 years, s.d. = 12.1), analysed speed of remission and found no difference. One RCT that analysed completers of a unilateral stimuli ECT (mean age 47.6, s.d. = 14.7) v. paroxetine comparison (mean age 52.3, s.d. = 15.7) in a sample of in-patients with treatment-resistant depression with an average of 4.9 antidepressant trials during the current episode, found the speed of response (50% decrease...
in HRSD-21) to ECT to be superior.26 In a RCT that compared bilateral ECT (mean age 57.4, s.d. = 14.1) with the addition of lithium (mean age 52.9, s.d. = 11.5) in a group of patients treated with tricyclic antidepressants, lithium addition resulted in a significantly faster decrease in HRSD score in week 1, although improvement in week 3 was not significantly different between the groups.27

Only one non-randomised study in elderly patients with psychotic depression12 has compared the speed of response in an ECT group (n = 17) and a medication (blood-level controlled nortriptyline combined with perphenazine) group (n = 8). In this study response was defined as a HRSD score ≤ 10 with absence of delusions and hallucinations, a definition which approaches our definition of remission. A superior speed of response in the ECT group was found compared with the medication group. Adjusted for the duration of the current episode, the hazard ratio for response after 8 weeks was 6.71 (95% CI 1.5–31.1) for ECT v. medication. Although the samples were small it is interesting that the favourable outcome of ECT in our study is in line with these results, especially when additional adjustments are made for the episode duration and number of antidepressants, with a hazard ratio of 8.2 (95% CI 3.6–19.0).

Findings from subgroup analysis
The brief pulse subgroup of the ECT study had a faster rate of remission (3.6 v. 4.6 weeks) and higher remission rate (68.4% v. 49.0%) than the ultrabrief pulse subgroup.15 In the medication RCT no statistical difference was found between the venlafaxine and nortriptyline groups regarding the speed of remission (7.1 v. 5.8 weeks, t(25) = 1.016, P = 0.319) and the remission rates (27.5% v. 39.0%; χ²(1) = 1.210, P = 0.271).16 Although it may be debatable whether merging of both ECT subgroups is allowed because the speed of remission differed significantly in the ECT subgroups, all comparisons between ECT subgroups and medication subgroups resulted in favour of the ECT subgroups.

Differences between the ECT and medication groups
Although the ECT and medication groups had many similarities at baseline partly because of our selection criteria, some differences emerged and we have adjusted the mean outcome results for these differences. The difference in number of antidepressants used between the ECT and medication group (2.4 v. 0.9) in this study fits the alleged time to complete at least one additional medication trial and is in line with the international guidelines.5,7 The difference in the mean duration of the current depressive episode (11.3 months for ECT v. 5.5 months for medication) may represent the necessary time for the extra medication trials, but may also represent extensive patient and doctor delays, in line with the reported hesitance of patients and reluctance of professionals to use ECT.10,14 Considering the evidence that with longer duration of the current depressive episode the efficacy of antidepressant treatment, ECT28,29 as well as medication,30,31 will diminish, this study suggests that the depressive burden and hospital stay may be significantly shortened by an earlier use of ECT.

Strengths and limitations
This is the first study focusing on the speed of remission and the largest study comparing ECT and medication in elderly patients with depression to date. The main limitation is that in this study results from two RCTs were used. Unknown and unsuspected confounders may not have been removed by randomisation to treatment. We were able to correct for many known important covariates but cognition, somatic and psychiatric comorbidity were assessed differently in each of the original trials and could therefore not be evaluated as potential confounders. Assessments were carried out by different groups of researchers, although both groups were trained in the use of depression ratings scales. The study assessments of the medication group were only available at baseline and in weeks 1, 3 and 5. To allow comparison between the groups at these four time points, three remissions that occurred in week 4 of the ECT study were counted in week 5, which resulted in a slight underestimation of the speed of remission with ECT.

Implications
Electroconvulsive therapy had a substantially higher speed of remission compared with antidepressants, although the patients in the ECT group had been depressed for significantly longer and had a higher degree of treatment resistance. Electroconvulsive therapy deserves a more prominent position in the treatment of elderly patients with severe unipolar depression.

References


